Two businessmen pushing giant puzzle pieces together as the sun sets behind them
Biotech

AbbVie inks $10.9B Apogee buyout to bag eczema prospect

The deal will give AbbVie control of a late-phase eczema drug candidate that could pose a threat to Eli Lilly, Regeneron and Sanofi.
Nick Paul Taylor Jun 22, 2026 7:59am
Kyle Diamantas

HHS unveils plan to speed up ph. 1 trials by 6 to 12 months

Jun 22, 2026 12:10pm
ipsen-heropng

Redefining PSC success through endpoint research.

Brought to you by Ipsen
fundraise tracker 2026

Fierce Biotech Fundraising Tracker '26: Triveni Bio & more

Jun 22, 2026 11:00am
For biopharma manufacturing at speed and scale the future is flexible

For biopharma manufacturing at speed and scale, the future is flexible

Brought to you by Resilience
Regenxbio

In another reversal, FDA to reconsider Regenxbio gene therapy

Jun 22, 2026 10:26am
More News

Merck anti-TL1A antibody from Prometheus buy passes ph. 3 test

Jun 22, 2026 10:17am

Definium’s LSD depression drug produces ‘best ever’ ph. 3 data

Jun 22, 2026 7:00am

Bionyra emerges with $165M and three licensed I&I assets

Jun 22, 2026 7:00am

Sanofi replaces R&D chief as new CEO seeks to kickstart pipeline

Jun 22, 2026 3:48am